GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets
King's College London · Health Data Research UK · +57 more institutions
Abstract
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is not fully explained by variation at robustly identified risk loci. To refine the genetic map of psoriasis susceptibility we meta-analysed 18 GWAS comprising 36,466 cases and 458,078 controls and identified 109 distinct psoriasis susceptibility loci, including 46 that have not been previously reported. These include susceptibility variants at loci in which the therapeutic targets IL17RA and AHR are encoded, and deleterious coding variants supporting potential new drug targets…
Citation impact
- FWCI
- 33.09
- Percentile
- 100%
- References
- 100
Authors
97- NDNick DandCorresponding
King's College London, Health Data Research UK
- PEPhilip E. Stuart
University of Michigan
- JBJohn Bowes
University of Manchester, Arthritis UK, Genomics (United Kingdom), NIHR Manchester Biomedical Research Centre
- DEDavid Ellinghaus
Christian-Albrechts-Universität zu Kiel
- JNJoanne Nititham
University of California, San Francisco
Topics & keywords
- Psoriasis
- Genome-wide association study
- Epigenetics
- Biology
- Transcriptome
- Disease
- Genetic predisposition
- Genetics
- Good health and well-being
Funding
- UDU.S. Department of Veterans Affairs
- MJMichael J. Fox Foundation for Parkinson's Research
- NPNational Psoriasis FoundationAward: 814364
- PPfizer
- SKStiftelsen Kristian Gerhard Jebsen
- AAA. Alfred Taubman Medical Research InstituteAward: P30AR075043
- NTNorges Teknisk-Naturvitenskapelige Universitet
- HMHelene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust
- MCMaudsley Charity
- EFEuropean Federation of Pharmaceutical Industries and Associations
- NINational Institute for Health and Care ResearchAwards: BRC-1215-20014, NIHR302258, 21754, NIHR203308
- MSMultiple Sclerosis Society
- KCKing's College London
- ECEuropean CommissionAwards: 390884018, 821511, CRC1181, 2020., 2014-2020, PUT1465
- DFDeutsche ForschungsgemeinschaftAwards: CRC1181, 236/8-1, SI236/9-1, 390884018, SI 236/8-1, EXC 2167-390884018, EXC 2167, ER 155/6-1, 2167-390884018
- ETEesti TeadusagentuurAwards: PRG1911, PRG1291, PUT1465, 2014-2020, 2014-2020.4.01.15-0012, PRG1189
- BFBundesministerium für Bildung und ForschungAwards: 01EC1401C, CRC1181, Metarthros 01EC1407A, 01EC1407A, BMBF Metarthros 01EC1407A
- UOUniversity of Toronto
- KFKrembil Foundation
- HMHelse Midt-Norge
- DZDeutsches Zentrum für Neurodegenerative Erkrankungen
- NFNorges Forskningsråd
- SOSt. Olavs Hospital Universitetssykehuset i Trondheim
- VAVersus ArthritisAward: 21754
- LFLEO Fondet
- HNHeinz Nixdorf StiftungAwards: SI 236/8-1, ER 155/6-1
- MSMultiple Sclerosis Society of Western Australia
- NINational Institutes of HealthAwards: R01AR050511, R01AR042742, R35GM138121, AR081033, UC2 AR081033, R01AR065183, P30AR075043, R01AR054966, P30 AR075043, U01AI119125, AR072129, AR075043, R01AR063611, R01AR065174
- UOUniversity of California, San Francisco
- IOInstitute of Psychiatry, Psychology and Neuroscience, King’s College London
- MBManchester Biomedical Research CentreAwards: 21754, NIHR203308
- NBNIHR BioResource
- NMNIHR Maudsley Biomedical Research Centre
- FFFakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet
- MRMedical Research CouncilAward: MR/S003126/1
- EREuropean Regional Development FundAwards: 2014-2020.4.01.15-0012, 2014-2020
- NCNIHR Cambridge Biomedical Research CentreAward: BRC-1215-20014
- FOFaculty of Medicine and Health, University of Sydney
- NINorwegian Institute of Public Health